首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Translational research strategy: an essential approach to fight the spread of antimicrobial resistance.
【24h】

Translational research strategy: an essential approach to fight the spread of antimicrobial resistance.

机译:翻译研究策略:对抗抗菌性抗性传播的必要方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Translation research strategy in infectious diseases, combining the results from basic research with patient-orientated research, aims to bridge the gap between laboratory findings and clinical infectious disease practice to improve disease management. In an era of increasing antimicrobial resistance, there are four main areas of clinical and scientific uncertainty that need to be urgently addressed by translational research: (i) early diagnosis of antibiotic-resistant infections and the appropriateness of empirical antibiotic therapy; (ii) the identification of reservoirs of antibiotic-resistant pathogens; (iii) the development of new antibiotics with lower propensities to evoke resistance; and (iv) the development of new non-antibiotic drugs to be used in the prevention of the spread of resistant bacterial strains. Strict European collaboration among major stakeholders is therefore essential. Appropriate educational tools to train a new generation of scientists with regard to a multifaceted approach to antimicrobial resistance research should be developed. Key areas include the support and implementation of European networks focused on translational research and related education activities, making potential therapeutics more attractive to investors and helping academic investigators to determine whether new molecules can be developed with clinical applicability.
机译:传输研究策略在传染病中,将基础研究与患者导向研究的结果相结合,旨在弥合实验室发现与临床传染病的差距,改善疾病管理。在增加抗菌性抗性的时代,有四个主要的临床和科学不确定性领域,需要通过翻译研究迫切地解决:(i)早期诊断抗生素抗性感染和经验抗生素治疗的适当性; (ii)鉴定抗生素抗性病原体的储层; (iii)开发新的抗生素,较低的诱发抗性; (iv)在预防抗性细菌菌株的扩散中使用新的非抗生素药物的开发。因此,严格的主要利益攸关方之间的欧洲合作是必不可少的。应开发适当的教育工具,用于培养新一代科学家关于多发性抗菌性抗性抗性研究的抗菌抗性研究。主要领域包括欧洲网络的支持和实施,重点是翻译研究和相关教育活动,使潜在的治疗方法对投资者更具吸引力,帮助学术调查人员确定新分子是否可以通过临床适用性发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号